Press Releases

May 14, 2023
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations  and Fulfill APD Customer Orders During Process BUFFALO, N.Y. , May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc.
Printer Friendly Version 
March 20, 2023
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million , or $4.28 per diluted share in 4Q2022, compared to $104.4 million , or $19.08 per diluted
Printer Friendly Version 
February 14, 2023
Athenex Announces a Reverse Stock Split
BUFFALO, N.Y. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20
Printer Friendly Version 
January 03, 2023
Athenex Announces MHRA Decision on Oral Paclitaxel
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issues Athenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major
Printer Friendly Version